Safety, Efficacy, and Dosage of 1% Pimecrolimus Cream for the Treatment of Atopic Dermatitis in Daily Practice

American Journal of Clinical Dermatology

Volumn 7, Issue 2, 2006, Pages 121-131

  Lübbe, Jann ^a   Friedlander, Sheila F ^b   Cribier, Bernard ^c   Morren, Marie Anne ^d   García Díez, Amaro ^e   Gelmetti, Carlo ^f   Hofmann, Heidelore ^g   Houwing, Ronald H ^h   Kownacki, Stephen ⁱ   Langley, Richard G B ^j   Virtanen, Marie ^k   Wolff, Klaus ^l   Wisseh, Steve ^m   McGeown, Claire ^m   Abrams, Beatrice ^m   Schneider, Dirk ^m  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f UNIVERSITY OF MILAN   (Italy)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h DEVENTER HOSPITAL   (Netherlands)

ⁱ Albany House Medical Centre   (United Kingdom)

^j DALHOUSIE UNIVERSITY   (Canada)

^k UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^l Universitatsklinik fur Dermatologie   (Austria)

^m NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL ETHER; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; DIPHENHYDRAMINE; FLUTICASONE PROPIONATE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; MOMETASONE FUROATE; PIMECROLIMUS; TRIAMCINOLONE;

ADOLESCENT; ADULT; AGED; APPLICATION SITE BURNING; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACTERIAL INFECTION; BRONCHITIS; BURN; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EAR INFECTION; EVALUATION; EXPERIENCE; FACE MALFORMATION; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; IMPETIGO; INFANT; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OTITIS MEDIA; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SINUSITIS; SKIN MANIFESTATION; SKIN PAPILLOMA; SORE THROAT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; TACROLIMUS;

EID: 33645867656     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607020-00005     Document Type: Article

References (54)

1. Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task-Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997; 79: 197-211
2. Williams HC. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 1992; 17: 385-91
3. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy 1993; 31: 9-28
4. Kay J, Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994; 30: 35-9
5. Williams H, Robertson G, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol 1999; 103: 125-38
6. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial costs. Arch Dis Child 1997; 76: 159-62
7. Lewis-Jones MS, Finlay AY, Dykes PJ. The infants' dermatitis quality of life index. Br J Dermatol 2001; 144: 104-10
8. Schiffner R, Schiffner-Rohe J, Landthaler M, et al. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003; 21: 159-79
9. Hepburn D, Yohn JJ, Weston WI. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994; 9: 225-54
10. Hanifin JM, Tofte SJ. Update of therapy of atopic dermatitis. J Allergy Clin Immunol 1999 Sep; 104 (3 Pt 2): S123-S5
11. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr 2000; 39: 1-14
12. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000; 1: 41-6
13. Hill CJ, Rosenberg Jr A. Adverse effects from topical corticosteroids. Cutis 1978; 21: 624-8
14. Stoppolino G, Prisco F, Santinelli R, et al. Potential hazards of topical steroid therapy. Am J Dis Child 1983; 137: 1130-1
15. Lewis-Jones S. Atopic dermatitis in childhood. Hosp Med 2001; 62: 136-43
16. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246-53
17. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986; 115: 475-84
18. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988; 118: 517-22
19. Goossens A. Contact allergic reactions on the eyes and eyelids. Bull Soc Belge Ophtalmol 2004; (292): 11-7
20. Foti C, Bonifazi E, Casulli C, et al. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis 2005; 52: 162-3
21. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976; 112: 1245-8
22. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979; 18: 23-31
23. Singh G, Singh PK. Tachyphylaxis to topical steroids measured by histamine-induced wheal suppression. Int J Dermatol 1986; 25: 324-6
24. Zheng PS, Lavker RM, Lehmann P, et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol 1984; 82: 345-52
25. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICAAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 (63 Suppl.): 3-10
26. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996; 35: 615-9
27. Paller A, McAllister RO, Doyle JJ, et al. Perception of physicians and pediatric patients about atopic dermatitis, its impact and its treatment. Clin Pediatr 2002; 41: 323-32
28. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996; 37: 10-3
29. Charman CR, Morris AD, Williams HC. Topical corticosteroids phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6
30. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000; 201: 242-5
31. McAlister RO, Tofte SJ, Doyle JJ, et al. Patient and physician perspectives vary on atopic dermatitis. Cutis 2002; 69: 461-6
32. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73
33. Stuetz A, Grassberger M, Meingassener JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41
34. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817-40
35. Meingassener JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76
36. Queille-Roussel C, Paul C, Duteil C, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol 2001; 144: 507-13
37. Van Leent EJM, Ebelin M-E, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopical dermatitis. Dermatology 2002; 204: 63-8
38. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643-55
39. Luger T, van Leent EJM, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-94
40. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144: 781-7
41. Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-7
42. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504
43. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
44. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: 1-8
45. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62
46. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004; 15: 169-78
47. Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52: 240-6
48. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-60
49. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003; 4: 641-54
50. David TJ, Cambridge GC. Bacterial infection and atopic eczema. Arch Dis Child 1986; 81: 20-3
51. Bonifazi E, Garofalo L, Pisani V, et al. Role of some infectious agents in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 98-100
52. Giannetti A. Viral skin diseases in atopic dermatitis. In: Happle R, Grosshans E, editors. Pediatric dermatology. Berlin: Springer-Verlag, 1987: 110-3
53. David TJ, Longson M. Herpes simplex infection in atopic eczema. Arch Dis Child 1985; 60: 338-43
54. Bork K, Brauninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988; 19: 1204-9